Protected: UTI resources – NSW

This content is password protected. To view it please enter your password below:

UTI resources

Pharmacists providing antibiotics for acute uncomplicated cystitis

Pharmacists in Queensland can supply antibiotics for uncomplicated Urinary Tract Infections (UTI) without a prescription, where appropriate. Authorisation to supply antibiotics for this purpose is provided under the Queensland Government Extended Practice Authority ‘Pharmacists’ (EPA).


What do Queensland pharmacists need to do?

  1. Complete the training program – available here
  2. Follow the Treatment guideline for pharmacists: acute uncomplicated cystitis – available here

What about pharmacists in other states?

Keep an eye on PSA member communications for updates to regulations around Australia.

Biological disease-modifying antirheumatic drugs (bDMARDS)

PSA has joined NPS MedicineWise and seven other organisations representing pharmacists, specialists, consumers and research experts to form the Targeted Therapies Alliance. The Alliance provides stewardship and direction about the safe and wise use of biological disease-modifying antirheumatic drugs (bDMARDs) and other specialised medicines.

Screening for cardiovascular disease risk in people living with HIV

The Pharmaceutical Society of Australia has developed a Screening for cardiovascular disease risk in people living with HIV checklist that can be used to help you screen for risk factors for CVD in your patients living with HIV and guide you to educate and refer those at increased risk to see their doctor for a comprehensive clinical assessment.

Digital Health Guidelines For Pharmacists

About the guidelines


The Digital Health Guidelines for Pharmacists describe the professional obligations of pharmacists when interacting with digital health systems in performing their professional clinical roles. These guidelines provide guidance on expected professional practice when using digital health systems, so that pharmacists can provide optimal patient outcomes, while meeting legal and ethical obligations relating to data access and stewardship. The guidelines should be used as a tool to support practice and professional decision making, and ensure that patients’ needs, beliefs and preferences are met. They can be used as an educational resource to inform quality assurance processes, and provide support when resolving legal disputes and ethical dilemmas.


The Digital Health Guidelines for Pharmacists are applicable to all settings in which pharmacists practise and interact with digital health, including settings where the pharmacist does not dispense medicines.


Guidelines produced by the Pharmaceutical Society of Australia (PSA) are not definitive statements of correct procedure but represent agreement by experts in the field. The guidelines do not set a prescribed course of action or a mandatory standard to which pharmacists must adhere.


The guidelines do not provide a technical guide on how to operate digital health systems; rather, they provide guidance on the minimum professional and ethical behaviour for pharmacists when using digital health systems in the delivery of health services.


Development of the Digital Health Guidelines for Pharmacists has been supported by the Australian Digital Health Agency. This document supersedes the My Health Record Guidelines for Pharmacists (2019), and incorporates much of this previous version. The work to update the guidelines included review by experts, stakeholder feedback, and the consensus of organisations and individuals involved. The Pharmaceutical Society of Australia thanks all those involved in the review process and, in particular, gratefully acknowledges the contribution of the following individuals and organisations.

Broad hierarchy of guidance and regulation of pharmacy practice v2

Pharmacists are expected to exercise professional judgement when adapting the guidance provided in these guidelines to specific circumstances. The guidelines sit within a broader hierarchy of guidance underpinning and supporting the practice of pharmacists working with digital health systems (see Figure 1).


It is important to review these guidelines in conjunction with the current versions of the:

  • Pharmacy Board of Australia Code of Conduct for Pharmacists

  • National Competency Standards Framework for Pharmacists in Australia

  • PSA Code of Ethics for Pharmacists

    • PSA Dispensing Practice Guidelines

    • PSA Professional Practice Standards

    • Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Display of Medicines Information (2017)

    • Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Presentation of Discharge Summaries (2017)

Guideline Sections

Note: Refresh your page is you have any difficulty opening the Guideline Section

7CPA Resources

The 7th Community Pharmacy Agreement, which commenced on 1 July 2020, provides certainty, stability and flexibility for the pharmacy profession for the next five years.

Treatment guidelines for pharmacists

Treatment guidelines for pharmacists (formerly known as S3 guidance documents) provide details of the recommended process for pharmacists to follow when supplying Pharmacist Only medicines.

Prescription Medication Safety

As the custodians of medication safety, promoting the judicious, quality and safe use of prescription medications is key to the pharmacist’s role. This interactive, two-part program will delve into the importance of prescription medication safety, the societal impact of the misuse of medicines, and the impact that medications and substances can have on fitness to drive. Proudly funded by NSW Government.


Click Here for more information

HIV Resources

HIV treatment has evolved rapidly over the past 30 years since the discovery of HIV. Since the development of zidovudine (AZT) in 1986, a large number of antiretroviral (ARV) classes have been developed, all of which aim to interrupt the HIV replication cycle at different stages. Taken in combinations of three of more medicines, treatment with ARVs can be complex, especially in instances where co-morbidities impact on treatment choice. Being confident with providing HIV ARVs for treatment will lead to a better patient experience, with these resources designed to aid in supporting the delivery of high-quality HIV treatment services within the pharmacy setting.

Immunisation Resources

The PSA immunisation resource hub provides members with a suite of education and resources to support your practice as an immuniser. We will also keep you updated on the work PSA is doing to support members and advocate for pharmacists to expand their role as immunisers.